Infliximab (Remicade) for the indication 'plaque psoriasis’

Infliximab and adalimumab, etanercept and ustekinumab are of equal therapeutic value in the treatment of adults suffering from mild to moderately severe plaque psoriasis who do not respond sufficiently to – or do not tolerate – other systemic therapies, including ciclosporin, methotrexate and PUVA.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.